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The aim of our study was to explore the clinicopathological and prognostic significance of extracellular matrix metalloproteinase
inducer (EMMPRIN) expression in oral squamous cell carcinomas (OSCC), and its relation with the proliferative tumor status
of OSCC. We examined EMMPRIN and Ki-67 proteins expression by immunohistochemistry in 74 cases with OSCC. Statistical
analysis was conducted to examine their clinicopathological and prognostic significance in OSCC. EMMPRIN membrane
expression was observed in all cases, with both membrane and cytoplasmic tumor expression in 61 cases (82.4%). EMMPRIN
overexpression was observed in 56 cases (75.7%). Moderately or poorly differentiated tumors showed EMMPRIN overexpression
more frequently than well-differentiated tumors (𝑃 = 0.002). Overexpression of EMMPRIN was correlated with high Ki-67
expression (𝑃 = 0.004). In the multivariate analysis, EMMPRIN overexpression reveals an adverse independent prognostic value
for cancer-specific survival (CSS) (𝑃 = 0.034). Our results reveal that EMMPRIN protein is overexpressed in more than two-thirds
of OSCC cases, especially in high proliferative and less differentiated tumors.The independent value of EMMPRIN overexpression
in CSS suggests that this protein could be used as an important biological prognostic marker for patients with OSCC. Moreover,
the high expression of EMMPRIN makes it a possible therapeutic target in OSCC patients.
1. Introduction
Oral cancer remains a major public health problem with
almost 300,000 new cases worldwide [1, 2]. New insights in
cancer diagnosis and therapy have not changed significantly
the survival rate for oral cancer (around 50%) during the last
decades [1].
Oral tumorigenesis is a multistep process caused by accu-
mulation of multiple genetic and epigenetic alterations [3].
The comprehension of the molecular pathways involved in
this process may originate special biological markers able to
differentiate tumors with a more or less aggressive behavior.
Thesemarkersmay contribute to identify and stratify patients
with greater precision to themost appropriate treatment plan.
Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 905680, 9 pages
http://dx.doi.org/10.1155/2014/905680
2 BioMed Research International
Moreover, these molecules could become molecular ther-
apeutic targets.
Extracellular matrix metalloproteinase inducer (EMM-
PRIN), also known as CD147, Basignin, M6, Neurothelin, or
gp42, is a highly glycosylated transmembrane protein, mem-
ber of the immunoglobulin superfamily of receptors, discov-
ered by its capacity of inducing the expression of matrix met-
alloproteinases [4]. It is present in epithelial cells, neuronal
or nerve cells, myocardial cells, lymphoid cells, or germ cells
and has an important role in several biological processes
such as fetal development, retinal function, development
of the nervous system and thymic T cell development [5].
EMMPRIN is expressed in several cancers including head
and neck squamous-cell carcinomas, pancreatic adenocar-
cinomas, kidney chromophobic carcinomas, hepatocellular
carcinomas,medullary breast adenocarcinomas, cervix carci-
nomas, and glioblastomas [5]. EMMPRIN contributes to cell
adhesion modulation, tumor growth, invasion, and angio-
genesis [4–7] probably due to its association with several
proteins implicated in different signaling pathways such as
matrix metalloproteinases, ErbB, MAPK cascade proteins,
monocarboxylate transporters (MCT), integrins, caveolin-1
(Cav-1), Tenascin (TN)-C, vascular endothelial growth factor
(VEGF), urokinase-type plasminogen activator (uPA), and
cyclophilins (Cyp) [4, 6, 8, 9].
Previous reports have shown that EMMPRIN expression
is associated with a high tumor aggressive behavior and
with poor prognosis in several tumors [10–19]. However, in
OSCC the prognostic significance of EMMPRIN is poorly
studied. Moreover, the relation of this glycoprotein with the
proliferative tumor capacity in patients with OSCC has not
been reported.
We aimed in this study to evaluate the expression of
EMMPRIN in patients with OSCC and investigate the asso-
ciation of this glycoprotein with clinicopathological, tumor
proliferation, and prognosis variables.
2. Material and Methods
2.1. Patient Recruitment. This retrospective study included
patients with newly diagnosed and consecutively treated
primary OSCC at the Hospital de Santo Anto´nio (HSA),
Porto, Portugal, between 2000 and 2006. The study was
approved by the institutional review board of the hospital.
From patient’s records, we obtained patient’s age, gender,
tumor location, tumor stage (I–IV), primary treatment, histo-
logical type, tumor grade, surgical margin status, and follow-
up information.
Patients were excluded if they lacked clinical and follow-
up information or if their paraffin blocks lacked sufficient
tumor tissue leaving 74 patients for this study, 55 men and
19 women, with a mean age of 62.3 ± 15.3 years (range from
25 to 96 years). Table 1 lists the clinicopathological features of
these patients.
Tumor stage was classified according to the 7th edition
of the classification of malignant tumors of American Joint
Committee on Cancer [20]. For all tumors, 3 𝜇m sections
were cut and stained with haematoxylin-eosin (HE) to
confirm the initial diagnosis. Tumor grade was reclassified
following the WHO classification (2005) into well-differ-
entiated (G1), moderately differentiated (G2), and poorly
differentiated (G3) OSCC [21]. Inspection for possible pres-
ence of tumor lymphatic invasion and perineural permeation
reported as present or absent was performed on each sample.
2.2. Tissue Microarray (TMA) Construction. Immunohisto-
chemistry was performed on tumor tissues using TMA
technology designed and constructed according to rules
previously described [22]. Briefly, representative tumor areas
were selected on haematoxylin and eosin-stained sections
andmarked on paraffin blocks, avoiding necrosis and keratin
areas. Three cylindrical tissue cores (2mm in diameter) were
obtained from each selected specimen and transferred to
a recipient paraffin block, using a microarray instrument
(TMA Builder, Histopathology Ltd., Hungary). From each
TMA block, 3 𝜇m sections were cut and processed for
immunohistochemistry.
2.3. Immunohistochemistry. TMA slides were deparaffinised
in xylene, dehydrated in an ethanol series, and rinsed in
distilled water. Epitope retrieval treatment was performed
using 0.01M citrate buffer (pH 6.0) for CD147 and 0.01M tri-
sethylenediaminetetraacetic acid (EDTA) buffer (pH 9.0)
for Ki-67 at high temperature (98∘C water bath during 30
minutes). After blocking endogenous peroxidase with meth-
anol containing 0.3% hydrogen peroxide (H
2
O
2
) for 5min,
sections were incubated with a blocking solution made of
0.4% casein in trisbuffered saline (TBS) to reduce nonspecific
binding. TMA slides were incubated with the primary mon-
oclonal antibody (anti-CD147, clone AB1843, Novocastra,
Newcastle upon Tyne, UK, diluted at 1 : 30; and anti-Ki-
67, clone MIB1, Dako, Glostrup, Denmark, diluted at 1 : 10)
during 60minutes at room temperature.Then the slides were
washed in TBS, followed by incubation with standard per-
oxidase-labelled dextran polymer for visualization with
diaminobenzidine as chromogen (NovoLink Polymer Detec-
tion System, Novocastra, Leica Biosystems Newcastle Ltd.),
according to themanufacturer’s instructions. TMA tissue sec-
tions were lightly counterstained with Mayer haematoxylin
for 2min and cover-slipped. Positive (skin and oral mucosa)
and negative (omission of primary antibody) controls were
used in each staining run.
2.4. Evaluation of Immunohistochemical Expression. All sam-
ples were evaluated by two authors blinded to clinicopatho-
logical characteristics. The discordant cases were reviewed
under a multihead microscope to achieve a consensus. We
used the higher score out of at least 2 of the 3 cores
examined per case. EMMPRIN staining was evaluated on
the basis of extent and intensity immunolabeling of tumor
cells. The intensity of staining was scored as 0 (absent), 1
(weak), 2 (moderate), and 3 (strong).The extent ofmembrane
tumor cells stainingwas semiquantitatively evaluated as 0 (no
labelling or labelling in <10% of tumor cells); 1 (labelling in
10% to 24% of tumor cells); 2 (labelling in 25% to 49% of
tumor cells); 3 (labelling in 50% to 74% of tumor cells); and
4 (labelling in 75% or more of tumor cells). The sum of the
intensity and extent scores was used as the final score (0–7).
BioMed Research International 3
Table 1: Clinicopathological characteristics of the 74 patients with OSCC and their association with EMMPRIN and Ki-67 expressions.
Factor 𝑁 (%) EMMPRIN overexpression Ki-67 high expression
𝑁 (%) 𝑃 value 𝑁 (%) 𝑃 value
All cases 74 (100%) 56 (75.7%) 38 (51.4%)
Gender
Female 19 (25.7%) 11 (63.2%) 0.140 8 (42.1%) 0.350
Male 55 (74.3%) 44 (80%) 30 (54.5%)
Age
<62 years 37 (50%) 30 (81.1%) 0.278 22 (59.5%) 0.163
≥62 years 37 (50%) 26 (70.3%) 16 (43.2%)
Location
Labial mucosa 7 (9.5%) 6 (85.7%)
0.430
1 (14.3%)
0.396
Floor of the mouth 10 (13.5%) 7 (70%) 8 (80%)
Tongue 24 (32.4%) 15 (62.5%) 13 (54.2%)
Buccal mucosa 5 (6.8%) 5 (100%) 2 (40%)
Retromolar trigone 11 (14.9%) 8 (72.7%) 5 (45.5%)
Hard palate 9 (12.2%) 8 (88.9%) 3 (55.6%)
Gingiva 8 (10.8%) 7 (87.5%) 4 (50%)
Tumor size
T1 13 (17.6%) 8 (61.5%)
0.132
6 (46.2%)
0.396T2 29 (39.2%) 20 (69%) 12 (41.4%)
T3 9 (12.2%) 9 (100%) 6 (66.7%)
T4 23 (31%) 19 (82.6%) 14 (60.9%)
N status
N0 41 (55.4%) 28 (68.3%)
0.349
16 (39%)
0.052N1 12 (16.2%) 11 (91.7%) 7 (58.3%)
N2 17 (23%) 14 (82.4%) 11 (64.7%)
N3 4 (5.4%) 3 (75%) 4 (100%)
Stage
I 12 (16.2%) 8 (66.7%)
0.064
6 (50%)
0.080II 23 (31.1%) 14 (60.9%) 7 (30.4%)
III 10 (13.5%) 10 (100%) 7 (70%)
IV 29 (39.2%) 24 (82.8%) 18 (62.1%)
Treatment modality
SG 28 (37.8%) 20 (71.4%)
0.633
12 (42.9%)
0.522SG + RT 23 (31.3%) 17 (73.9%) 13 (56.5%)
CT + SG or RCT 23 (31.3%) 19 (82.6%) 13 (56.5%)
Tumor grade
G1 42 (56.8%) 26 (61.9%) 0.002 16 (38.1%) 0.009
G2 + G3 32 (43.2%) 30 (93.8%) 22 (68.8%)
Margin status∗
Free of tumor 33 (57.9%) 23 (69.7%) 0.423 14 (42.4%) 0.236
With tumor 24 (42.1%) 19 (79.2%) 14 (58.3%)
Perineural permeation
Absent 66 (89.2%) 50 (75.8%) 0.962 33 (50%) 0.504
Present 8 (10.8%) 6 (75%) 5 (62.5%)
Lymphatic invasion
Absent 58 (78.4%) 46 (79.3%) 0.165 30 (51.7%) 0.903
Present 16 (21.6%) 10 (62.5%) 8 (50%)
SG: surgery; RT: radiotherapy; CT: chemotherapy; RCT: radiochemotherapy.
∗Not determined in the 17 cases.
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Figure 1: Immunohistochemical expression of EMMPRIN and Ki-67 in oral squamous cell carcinomas: (A) EMMPRIN score 1+ expression
with predominantly peripheral distribution pattern (arrow) (×200); (B) EMMPRIN score 3+ expression with staining homogeneously
distributed by the tumor islands (×100). Inset: highermagnification (×400). Note peritumoral fibroblast staining (arrow); (C)Ki-67 expression
in less than 50% of tumor cells (×400); (D) Ki-67 expression in more than 50% of tumor cells (×400).
Tissues having a final score of 0-1 were considered negatives.
Final scores of 2-3, 4-5, and 6-7 were considered 1+, 2+, and
3+, respectively. For data analysis, score 3+ was defined as
EMMPRIN overexpression [12].
For Ki-67 evaluation, we considered the percentage of
nuclear staining for scoring proliferative status. We classified
tumors into two groups: low proliferative tumor (labelling
from 0 to 49% of tumor cells) and high proliferative tumor
(labelling in 50% or more of tumor cells) [23].
2.5. Statistical Analysis. Statistical analysis was carried out
using IBM SPSS Statistics version 21.0 software (IBM Cor-
poration, NY, US).The associations between categorical vari-
ables were evaluated by chi-square tests. Correlation between
EMMPRIN and Ki-67 was measured by Spearman’s correla-
tion coefficient. Cancer-specific survival (CSS) was defined
as the time interval (months) between primary treatment and
death fromoral cancer or last follow-up. Recurrence-free sur-
vival (RFS)was defined as the time interval (months) between
primary treatment and the first recurrence (whether local,
regional, or distant). The Kaplan-Meier method was used to
plot survival curves and their prognostic effect was tested
using the log-rank test. Variables with significant effects in
the univariate analyses were entered into Cox proportional
hazards model to investigate the independent effects of these
variables. Differences were considered statistically significant
at 𝑃 < 0.05.
3. Results
3.1. EMMPRIN Expression. Immunohistochemistry was per-
formed in 74 human OSCC tissues to evaluate the extent
and patterns of EMMPRIN protein expression. All cases
presented membrane staining for EMMPRIN on tumor cells.
Additionally, in 61 cases (82.4%), cytoplasmic expression
was also observed. On the basis of EMMPRIN immuno-
expression, cases were classified as 1+ in 2 (2.7%), 2+ in
16 (21.6%), and 3+ in 56 (75.7%) cases (Figures 1(A) and
1(B)). Staining of this protein was detected predominantly
at the periphery of the tumor islands (45; 60.8%) or present
homogenously within the tumor islands (29; 39.2%) (Figures
1(A) and 1(B)). We observed also that EMMPRIN expression
was seen in peritumoral fibroblasts in 65 (87.8%) cases
(Figures 1(A) and 1(B)). Fibroblasts were identified by an
experienced pathologist based on its histomorphological
features. In cases in which difficulties existed in fibroblast
identification, we recurred to coloration for vimentin and
smooth muscle actin. Apparently, normal mucosa adjacent
to primary tumor presented a strong EMMPRIN staining in
basal and suprabasal epithelial layers.
We compared EMMPRIN expression in OSCC tissue
samples with patient clinicopathological variables. A posi-
tive association of EMMPRIN expression with histological
grade was noted where G2/G3 tumors presented EMMPRIN
overexpression more often than G1 tumors (𝑃 = 0.002)
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Figure 2: Kaplan-Meier curves according to EMMPRIN expression
demonstrating aworse cancer-specific survival in theOSCCpatients
with overexpression of this protein.
(Table 1). Although no significant association was found
between EMMPRIN overexpression and clinical stage, when
we divided clinical stage into initial stage (I/II) tumors
and advanced stage tumors (III/IV), we observed a signif-
icant association between EMMPRIN overexpression and
advanced tumor stages (𝑃 = 0.015). No other significant
relationship between EMMPRIN expression and the listed
clinicopathological parameters was found. Moreover, we did
not find significant relationship between EMMPRIN distri-
bution pattern (homogeneously or peripherically), EMM-
PRIN fibroblast staining, and the listed clinicopathological
parameters.
3.2. EMMPRIN and Ki-67 Correlation. Ki-67 expression was
detected in 72 cases (97.3%). Thirty-six cases (48.6%) were
classified as low proliferative tumors and 38 (51.4%) as high
proliferative tumors (Figures 1(C) and 1(D)). The intensity of
the marker was similar and homogeneous in almost all cases.
The only association between Ki-67 and the clinicopatho-
logical variables was observed with histological grade (𝑃 =
0.009) (Table 1).
EMMPRIN was positively correlated with Ki-67 expres-
sion (𝜌 = 0.33; 𝑃 = 0.004). Tumors with EMMPRIN over-
expression (𝑛 = 56) presented highKi-67 expression in 64.7%
(𝑛 = 34) of the cases. By contrast, only 22.2% (4/18) of tumors
without EMMPRIN overexpression expressed high levels of
Ki-67 protein.
3.3. Survival Analysis. The mean follow-up for all patients
was 36.45 ± 31.7 months and mean follow-up for living
patients was 52.05±33.02months. At the end of our study, 39
patients (52.7%) were alive without oral cancer, one patient
(1.4%) was alive with oral cancer, 33 (44.6%) had died as a
result of the oral cancer, and one patient (1.4%) had died
as a result of cardiovascular disease. The cumulative 3-year
cancer-specific survival (CSS) rate was 55.8% and recurrence-
free survival (RFS) was 46.6%.
On a univariate analysis using the Kaplan-Meier method
and log-rank test, we measured the influence of the clinical-
pathological and immunoexpression variables on the sur-
vival of patients with OSCC. EMMPRIN overexpression
was statistically associated with a worse CSS (𝑃 = 0.011)
(Figure 2; Table 2). Among the clinicopathological charac-
teristics, tumor size (𝑃 < 0.001), 𝑁 status (𝑃 = 0.003),
tumor stage (𝑃 < 0.001), treatment modality (𝑃 = 0.05),
and histological grade (𝑃 = 0.037) were also statistically
associated with a worse CSS (Table 2). As also described in
Table 2, we observed a significant association between RFS
and gender (𝑃 = 0.013), tumor size (𝑃 = 0.009), 𝑁 status
(𝑃 = 0.006), tumor stage (𝑃 = 0.009), margin status (𝑃 =
0.003), and perineural permeation (𝑃 = 0.041).
In themultivariate analyses usingCox regressionmethod,
we found an association of EMMPRIN overexpression with
poor survival (𝑃 = 0.034; Table 3), thus revealing EMMPRIN
overexpression as an adverse independent prognostic factor
for CSS in OSCC. In RFS, gender (𝑃 = 0.030) and margin
status (𝑃 = 0.019) reveal an independent prognostic value
for these tumors (Table 4).
4. Discussion
Recent studies have reported the biological and clinical
role of EMMPRIN receptor in several cancers in the last
decades [4, 5, 24]. However, the influence of this receptor
in OSCC is poorly understood. In the present study, we
aimed to evaluate the expression of EMMPRIN protein in
OSCC and to analyse the correlation of this receptor with
clinicopathological characteristics, tumor proliferation, and
patient’s outcome.
Our study showed that EMMPRIN protein was present in
all OSCC cases and overexpressed inmore than two-thirds of
the cases. This result is in accordance with the notably high
expression of this glycoprotein in squamous cell carcinomas
of head and neck region reported by Riethdorf et al. [5].
By analyzing EMMPRIN expression in multitumor TMAs,
they observed expression in more than 95% of squamous cell
carcinoma of oral cavity and 100% in squamous cell carci-
nomas of salivary glands. Lower expression values have been
reported by Gou et al. [25] in laryngeal carcinomas (87.5%),
Zhu et al. [17] in esophageal squamous cell carcinomas (85%),
and Huang et al. [11] in tongue squamous cell carcinomas
(67%). They also observed a significantly higher expres-
sion on tumor cells than in the noncancerous epithelium.
Vigneswaran et al. [26] found a strong EMMPRIN expression
in more than 90% of tumor cells in carcinoma in situ and
early-invasive OSCC and also a significant higher expression
compared with normal oral mucosa. The authors also found
an increasing expression of this marker in oral leukoplakias
gradually correlated with the degree of dysplasia, suggesting
that EMMPRIN overexpression occurs at an early step of oral
carcinogenesis and contributes to oral tumorigenesis. These
data highlight the potential important role of EMMPRIN in
OSCC.
We observed EMMPRIN expression in tumor cell mem-
brane and also in the cytoplasm of some cases, in concor-
dance with other studies [12, 14, 19]. Although our aim was
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Table 2: Univariable analysis of cancer-specific and recurrence-free survivals (at 3-years of follow-up).
Factor 𝑁 Dead Cancer-specificsurvival 𝑃 value 𝑁 Recurrence
Recurrence-free
survival 𝑃 value
Gender
Female 19 10 52.1 0.265 15 11 33.3 0.013
Male 55 23 57.8 47 20 50.7
Age
<62 yrs 37 19 46.4 0.324 29 16 37.7 0.546
≥62 yrs 37 14 65.2 33 15 54.1
Location
Lip 7 1 83.3
0.491
7 1 83.3
0.383
Tongue 10 5 70 10 8 20
Floor of the mouth 24 10 61.3 20 8 63.3
Gingiva 5 2 60 4 2 50
Retromolar trigone 11 6 30.7 8 4 37.5
Hard palate 9 4 53.3 7 4 42.9
Buccal mucosa 8 5 37.5 6 4 33.3
Tumor size
T1 13 1 88.9
<0.001
13 4 83.3
0.009T2 29 9 70.4 28 12 53.4
T3 9 5 30.5 8 5 30
T4 23 18 16.9 13 10 23.1
N status
0 41 11 76.9
0.003
37 13 63.5
0.0061 12 7 17.8 10 7 18
2 17 13 24.2 13 10 15.4
3 4 2 50 2 1 50
Stage
I 12 1 88.9
<0.001
12 4 71.6
0.009II 23 6 77.4 22 8 60
III 10 5 33.3 9 5 34.6
IV 29 21 26.9 19 14 23.7
Tumor grade
G1 42 13 67.8 0.037 36 15 55.7 0.195
G2/G3 32 20 42.1 26 16 35.3
Treatment modality
SG 28 28 76.2
0.050
26 10 55.2
0.134SG + RT 23 23 47.7 21 13 32.8
CT + SG or RCT 23 23 37.8 15 8 50
Margin status∗
Free of tumor 33 9 79.7 0.157 31 9 68.4 0.003
With tumor 24 11 50.1 23 16 26.1
Perineural permeation
Absent 66 28 58.2 0.243 54 25 49.8 0.041
Present 8 5 37.5 8 6 25
Lymphatic invasion
Absent 58 27 55.1 0.849 47 24 46.5 0.824
Present 16 6 61.1 15 7 53.3
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Table 2: Continued.
Factor 𝑁 Dead Cancer-specificsurvival 𝑃 value 𝑁 Recurrence
Recurrence-free
survival 𝑃 value
EMMPRIN expression
0, 1+, 2+ 18 3 88.5 0.011 17 8 58.8 0.882
3+ (overexpression) 58 30 45.7 45 23 43.3
EMMPRIN distribution
Homogeneous 45 18 59.2 0.503 37 18 50.5 0.898
Heterogeneous (periphery) 29 15 50.7 25 13 39.6
EMMPRIN fibroblasts
Absent 9 6 20.8 0.092 8 6 18.8 0.088
Present 65 27 60.1 54 25 50.6
Ki-67
<50% (low expression) 36 12 69.4 0.111 32 14 56.2 0.560
≥50% (high expression) 38 11 45 30 17 39.7
SG: surgery; RT: radiotherapy; CT: chemotherapy; RCT: radiochemotherapy.
∗Not determined in the 17 cases.
Table 3: Multivariable analysis of cancer-specific survival on vari-
ables with significant effect in univariable analysis.
Variablea 𝑃 value HR 95% CI
Stage 0.205 1.640 0.763–3.524
T status 0.075 1.824 0.941–3.532
N status 0.353 0.799 0.497–1.283
Treatment modality 0.673 1.110 0.685–1.797
Tumor grade 0.411 1.405 0.624–3.160
EMMPRIN expression 0.034 3.894 1.106–13.709
HR: hazard ratio; CI: confidence interval for HR.
aVariables included in multivariable Cox regression analysis using enter
method; stage (ordinal variable); T status (ordinal variable); N status (ordinal
variable); treatmentmodality (ordinal variable); tumor grade,G2+G3 versus
G1 (reference category); EMMPRIN expression, positive versus negative
(reference category).
to analyse the expression of EMMPRIN in tumour cells, we
detected the presence of this receptor in peritumoral fibro-
blasts as described by Vigneswaran et al. [26]. Furthermore,
EMMPRIN expression showed a predominantly periph-
eric/basal distribution pattern in the tumor islands in most
of our cases. This was reported in other works suggesting a
more frequent distribution of this receptor in tumor cells with
a more proliferative phenotype [11, 26].
In order to assess the relationship of EMMPRIN with
proliferative activity, we evaluated the expression of Ki-67
in these tumors and found a significant correlation between
these two proteins. To our knowledge, this correlation has not
been reported in OSCC, although Yang et al. [14] described a
positive association between EMMPRIN expression and Ki-
67 index labelling and also with tumor size in adenoid cystic
carcinomas. Similar results were reported by Zheng et al.
[27] showing a positive correlation between the two markers
in gastric carcinomas. These results are in line with ours,
suggesting that EMMPRIN might be relevant for the tumor
proliferation and tumor growth of OSCC. Furthermore,
Table 4: Multivariable analysis of recurrence-free survival on
variables with significant effect in univariable analysis.
Variablea 𝑃 value HR 95% CI
Gender 0.030 2.849 1.110–7.315
Stage 0.384 1.589 0.560–4.512
T status 0.365 1.372 0.693–2.718
N status 0.700 0.836 0.337–2.077
Margin status 0.019 3.081 1.205–7.879
Perineural permeation 0.498 1.454 0.492–4.294
HR: hazard ratio; CI: confidence interval for HR.
aVariables included in multivariable Cox regression analysis using enter
method; gender, female versus male (reference category); stage (ordinal
variable); T status (ordinal variable); N status (ordinal variable); margin
status, with tumor versus without tumor (reference category); perineural
permeation, present versus absent (reference category).
knockdown of EMMPRIN in head and neck carcinomas
decreased cellular proliferation and tumor growth in vitro
and in vivo analyses [28–30]. Mechanisms involved in tumor
proliferation via EMMPRIN are poorly understood, but some
authors have described the role of this receptor in association
with cyclophilin A in the activation of ERK1/2 and p38
pathways [31].
We found that EMMPRIN expression was significantly
associated with histological grade. Moderately or poorly dif-
ferentiated tumors showed more EMMPRIN overexpression
than well-differentiated tumors. Zhu et al. [17] observed the
same positive association in 86 esophageal squamous cell
carcinomas. Clinical stage and tumor size have been posi-
tively related with EMMPRIN expression in several cancers
including head and neck cancers [11, 12, 25]. We observed
that EMMPRIN overexpression was more frequently found
in patients with advanced clinical stage (III/IV), emphasizing
the biological significance of thismarker to tumor growth and
progression of OSCC. We did not find any other significant
relation with other clinicopathological parameters although
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association with nodal metastasis was observed by others
[32].
The influence of EMMPRIN expression on patient’s sur-
vival has been reported in glioblastomas, seminomas, and
other cancers including tongue, salivary gland, esophageal,
ovary, colorectal, breast, bladder, and lung cancers [11–15,
17, 19, 33–36]. In our univariate analysis, we found that
cases with EMMPRIN overexpression were associated with
a lower CSS (𝑃 = 0.011) additionally with other clinical
variables such as TNM and clinical stage. Nevertheless, in
the multivariate analysis for CSS, EMMPRIN protein was the
only independent prognostic factor (𝑃 = 0.034), revealing the
adverse independent impact of EMMPRIN overexpression
on the survival of patients with OSCC. To our knowledge,
this is the first report of the independent prognostic value
of EMMPRIN in a cohort of patients with squamous cell
carcinoma of the oral cavity. Previously, Huang et al. [11]
described the independent significant influence of this recep-
tor in the overall survival of patients with squamous cell
carcinomas of the tongue. This could be an important result
suggesting the use of this receptor as a prognostic biomarker
in OSCC. Interestingly, some studies report that EMMPRIN
might be even a predictivemarker of chemoresistance in head
and neck carcinomas [8]. The influence of this receptor on
patient’s prognostic could be related to themultiple biological
functions of this protein on tumor cells such as proliferation,
migration, invasion, angiogenesis, and dissemination on
OSCC [4]. Studies have described the role of EMMPRIN in
the stimulation of several metalloproteinases and proangio-
nenic factors from tumor and adjacent stroma cells that could
contribute to tumor multistep pathogenesis [27]. It would be
interesting to analyse the relationship of EMMPRIN expres-
sion and molecules involved in different pathways, such as
EGFR, MMP’s, and VEGFR’s, in a larger sample of OSCC.
The understanding of the different pathways involved
in oral tumorigenesis could reveal new candidate target
molecules for anticancer drugs. Anti-EGFR targeted ther-
apies are currently available for head and neck cancer but
with modest results [37]. New anticancer therapies directed
to molecular targets on oral cancer cells are needed and some
molecules have been proposed, including EMMPRIN recep-
tor [5, 9, 11, 38].The high expression of this receptor inOSCC,
the cell membrane location, the biological role on tumor
growth, invasion, dissemination, and the influence in the
patient’s prognosis make EMMPRIN a strong candidate for
a potential molecular target for monoclonal therapies against
this receptor in OSCC. Anti-EMMPRINmolecular therapies
showed growth inhibitory effect on head and neck squamous
cell carcinoma, alone and in combination with radiotherapy
in vitro and in vivo [39]. Sweeny et al. [40] reported a
promising extracellular drug conjugate (EDC22), capable of
inhibiting HNSCC cell proliferation in vitro and in vivo, with
better results than with radiation or cisplatin monotherapy.
In conclusion, our results reveal that EMMPRIN protein
is frequently overexpressed in OSCC, especially in high
proliferative tumors, suggesting that it might be involved
in the growth of these tumors. The independent value of
EMMPRIN overexpression in CSS indicates that this protein
could be used as an important biological prognostic marker
to identify high risk OSCC patients, helping in making the
right decision as to the appropriate treatment. Furthermore,
the high expression of this receptor could be regarded as
potential therapeutic target against OSCC.
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